Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Current Leases (2016 - 2025)

Amicus Therapeutics' Current Leases history spans 10 years, with the latest figure at $8.7 million for Q4 2025.

  • For the quarter ending Q4 2025, Current Leases rose 3.38% year-over-year to $8.7 million, compared with a TTM value of $8.7 million through Dec 2025, up 3.38%, and an annual FY2025 reading of $8.7 million, up 3.38% over the prior year.
  • Current Leases for Q4 2025 was $8.7 million at Amicus Therapeutics, up from $8.7 million in the prior quarter.
  • The five-year high for Current Leases was $8.7 million in Q4 2025, with the low at $6.8 million in Q1 2021.
  • Average Current Leases over 5 years is $8.0 million, with a median of $8.1 million recorded in 2023.
  • Year-over-year, Current Leases decreased 16.56% in 2021 and then grew 15.43% in 2022.
  • Tracing FOLD's Current Leases over 5 years: stood at $7.4 million in 2021, then increased by 15.43% to $8.6 million in 2022, then decreased by 2.67% to $8.3 million in 2023, then increased by 1.57% to $8.5 million in 2024, then grew by 3.38% to $8.7 million in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Current Leases are $8.7 million (Q4 2025), $8.7 million (Q3 2025), and $8.6 million (Q2 2025).